• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval - Learn Why

    Simply Wall St·07/31/2026 04:33:31
    Listen to the news
    • ImmunityBio recently reported that the Emirates Drug Establishment granted Marketing Authorization in the UAE for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, expanding the drug’s regulatory reach to 34 countries with its broadest label yet.
    • This is the first worldwide approval to cover the full spectrum of BCG-unresponsive bladder disease, including both carcinoma in situ and papillary-only tumors, while also adding a checkpoint-refractory lung cancer population, potentially broadening ANKTIVA’s treated patient base across two difficult-to-treat settings.
    • We’ll now examine how this expanded UAE approval for ANKTIVA, especially its first-in-class papillary-only bladder label, reshapes ImmunityBio’s investment narrative.

    Find 56 companies with promising cash flow potential yet trading below their fair value.

    ImmunityBio Investment Narrative Recap

    To own ImmunityBio, you need to believe ANKTIVA can sustain and broaden its role as the company’s core oncology asset while ImmunityBio works to reduce heavy losses and diversify beyond bladder cancer. The UAE’s broad approval reinforces the global ANKTIVA story, but the near term focus still sits on the FDA review for the papillary-only NMIBC label expansion in early 2027, with the key risk remaining execution on trials and real world uptake across newly opened markets.

    Among recent developments, the FDA’s acceptance of the supplemental Biologics License Application for ANKTIVA plus BCG in BCG-unresponsive papillary-only NMIBC is most relevant here. The UAE’s first in class inclusion of papillary disease alone effectively previews what ImmunityBio is seeking in the U.S., tying this international win directly to the company’s most important near term regulatory catalyst and highlighting how global and U.S. label evolution may now be more interconnected.

    Yet even as ANKTIVA’s footprint widens, investors should be aware that...

    Read the full narrative on ImmunityBio (it's free!)

    ImmunityBio’s narrative projects $1.6 billion revenue and $673.2 million earnings by 2029. This requires 125.9% yearly revenue growth and about a $1.53 billion earnings increase from -$854.5 million today.

    Uncover how ImmunityBio's forecasts yield a $13.00 fair value, a 74% upside to its current price.

    Exploring Other Perspectives

    IBRX 1-Year Stock Price Chart
    IBRX 1-Year Stock Price Chart

    Before this UAE approval, the most bullish analysts were already modeling about US$1.7 billion of revenue and US$734 million of earnings by 2029, which is far more optimistic than consensus and could shift further as new data and approvals reshape how you weigh ANKTIVA’s global execution risk against that ambitious growth path.

    Explore 10 other fair value estimates on ImmunityBio - why the stock might be worth less than half the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    No Opportunity In ImmunityBio?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.